Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine + Encorafenib + Cetuximab/Panitumumab in BRAF V600E Metastatic Colorectal Cancer
NCT05576896Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine in colorectal cancer (CRC), sponsored by Northwestern University. Primary endpoint: Objective Response Rate. Started Oct 2022; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05576896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576896.